CollPlant Biotechnologies announced on August 19, 2024, the initiation of a preclinical study for its regenerative breast implants in collaboration with Stratasys. This study utilizes 200cc commercial-sized implants printed using CollPlant's bioinks and Stratasys' Origin® 3D printer.
The collaboration between CollPlant and Stratasys is focused on developing a bioprinting solution for CollPlant's breast implants. This includes finding solutions to scale up the implant's fabrication process, which is critical for future commercialization.
This strategic partnership leverages Stratasys' expertise in 3D printing with CollPlant's proprietary rhCollagen technology. The aim is to advance the development of these novel implants, which are designed to regenerate breast tissue and offer a safer alternative to current options.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.